Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus

Simple item page
dc.contributor.authorVan Der Laan, L.
dc.contributor.authorHudson, M.
dc.contributor.authorMcPherson, S.
dc.contributor.authorZondervan, P.
dc.contributor.authorThomas, R.
dc.contributor.authorKwekkeboom, J.
dc.contributor.authorLindsay, A.
dc.contributor.authorBurt, A.
dc.contributor.authorKazemier, G.
dc.contributor.authorTilanus, H.
dc.contributor.authorBassendine, M.
dc.contributor.authorMetselaar, H.
dc.date.issued2010
dc.description.abstractA 2-center retrospective analysis was performed in 60 patients undergoing liver transplantation for hepatitis C virus (HCV)–related disease (cyclosporine in 20, tacrolimus in 40). Mean (±SEM) follow-up was 23.6 ± 22.5 and 22.3 ± 13.7 months in patients receiving cyclosporine or tacrolimus, respectively. Clinically indicated biopsies were performed in 15/20 cyclosporine patients (75%) and 22/40 tacrolimus patients (55%; P = .17). The Ishak fibrosis score was significantly lower in cyclosporine-treated patients versus tacrolimus-treated patients (mean 1.7 ± 0.4 vs 3.1 ± 0.4; P = .023), as was percentage of fibrosis grade Ishak ≥4 (7% vs 41%; P = .028). The mean time to moderate fibrosis (Ishak score ≥3) was 38.2 ± 15.1 months in cyclosporine patients (4/15) and 23.5 ± 12.6 months in tacrolimus patients (14/22); the difference was not statistically significant (P = .09). This retrospective study suggests that cyclosporine-based immunosuppression is associated with less severe hepatic fibrosis in HCV-positive liver transplant recipients compared with tacrolimus-based regimens, but a larger prospective comparative trial is necessary to confirm these findings.
dc.description.statementofresponsibilityL.J.W. van der Laan, M. Hudson, S. McPherson, P.E. Zondervan, R.C. Thomas, J. Kwekkeboom, A.S. Lindsay, A.D. Burt, G. Kazemier, H.W. Tilanus, M.F. Bassendine, H.J. Metselaar
dc.identifier.citationTransplantation Proceedings, 2010; 42(10):4573-4577
dc.identifier.doi10.1016/j.transproceed.2010.10.013
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.orcidBurt, A. [0000-0002-3011-7774]
dc.identifier.urihttp://hdl.handle.net/2440/83310
dc.language.isoen
dc.publisherElsevier Science Inc
dc.rights© 2010 by Elsevier Inc. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.transproceed.2010.10.013
dc.subjectHumans
dc.subjectHepatitis C
dc.subjectLiver Cirrhosis
dc.subjectDisease Progression
dc.subjectTacrolimus
dc.subjectCyclosporine
dc.subjectImmunosuppressive Agents
dc.subjectLiver Transplantation
dc.subjectRetrospective Studies
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.titleResults of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications